Pharmaceutical Technology

AUGUST 16, 2022

Enhertu has already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma, with annual sales for these indications alone expected to exceed $1.3bn by 2028.

Chemotherapy 59

Chemotherapy Immunity Immunization 59

Pharmaceutical Technology

AUGUST 12, 2022

Adoptive cell therapy (ACT) is a form of cancer treatment that involves the transfer of immune cells into a patient to help fight the disease, by eliminating cancer cells. By 2028, the market is expected to reach $25 billion, with a compound annual growth rate (CAGR) of 46.6%. billion in 2021 and is forecast to reach $2.4

Immunity 52

Immunity Immunization Chemotherapy Compounding 52

European Pharmaceutical Review

NOVEMBER 1, 2023

Pneumococcal Vaccines Market Size & Share Analysis – Growth Trends & Forecasts 2023-2028. The current state of immunization against Gram-negative bacteria in children: a review of the literature. 2022 [cited May2023], Available from: [link] Murray CJ, Ikuta KS, Sharara F, et al. The Lancet. 2022; 399(10325): 629–55.

Vaccines 115

Vaccines Immunity Immunization Drug Development 115

Pharmaceutical Technology

AUGUST 24, 2022

More than three decades ago, scientists at the National Cancer Institute began exploring ways to fight cancer using the patient’s immune system. CAGR between 2020 and 2028. CAGR between 2020 and 2028. Their work formed the basis of what is now a promising cancer treatment that doesn’t require surgery or radiation.

Method Validation 52

Method Validation Immunity Immunization Drug Development 52

Pharmaceutical Technology

OCTOBER 28, 2022

What’s more, VAX-24 achieved a higher immune response to 16 of the 20 serotypes it shares with Prevnar 20. billion and $812 million in 2028. On October 26, Vaxcyte stated that this offering was expected to yield approximately $600 million in gross proceeds The company now has a market cap of $2.47 Further plans in the making.

Vaccines 64

Vaccines Immunity Immunization 64

Pharmaceutical Technology

FEBRUARY 13, 2023

GlobalData’s analyst consensus forecast database estimates peak annual sales for ARV-110 of $325 million in 2028. However, on-target adverse events are also common with BTKis as they inhibit B-cell immune responses, which can result in serious infections. with Calquence, 16% with Imbruvica, NCT02477696).

Dosage 59

Dosage Chemotherapy Compounding Immunity 59

PharmaShots

JUNE 1, 2023

We are very pleased to demonstrate that our innovative immunotherapy platform can induce a strong immune response in humans. We reported at ESMO-IO the analysis of immune response of the first 3 cohorts of patients. Anti-PD-1 antibodies have recently become standard first-line treatments for melanoma and NSCLC. 2015; Zhu et al.,

Immunity 40

Immunity Immunization Vaccines Health and Personal Care Stores 40

STAT

NOVEMBER 19, 2024

patent expires in 2028. Keytruda is a cancer immunotherapy, which stimulates the immune system to attack tumor cells. It is the best-selling medicine in the world. Continue to STAT+ to read the full story…

Immunization 335

Immunization Immunity 335

Express Pharma

NOVEMBER 13, 2024

UCB and Biogen will likely leverage dapirolizumab’s unique CD40L-targeting MoA, a distinction that, according to the key opinion leaders interviewed by GlobalData, holds significant relevance for addressing the pathophysiology of lupus as a key driver of dysregulated immune responses.

Labelling 105

Labelling Immunity Immunization 105

Express Pharma

DECEMBER 9, 2024

Under this scheme, high-value pharmaceutical products such as patented/off-patented drugs, biopharmaceuticals, complex generics, anti-cancer drugs, auto-immune drugs, orphan drugs etc. The scheme provides financial incentives for the manufacturing of notified products. PLI Scheme for Pharmaceuticals, with a financial outlay of Rs.

Immunity 102

Immunity Immunization 102